Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients
- 1 October 2004
- journal article
- clinical trial
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 43 (7), 650-656
- https://doi.org/10.1080/02841860410032885
Abstract
Ten-year follow-up results are presented of an adjuvant clodronate trial in patients with primary breast cancer. Between 1990 and 1993, 299 women with primary node positive breast cancer were randomized to oral clodronate 1600 mg daily (149) or controls (150) for 3 years. All patients received adjuvant chemo- or endocrine therapy. Within 10 years bone metastases were detected at the same frequency in the clodronate and control groups: 44 (32%) vs. 42 (29%), respectively, (p=0.35). The frequency of non-skeletal recurrences (visceral and local) was significantly higher in the clodronate group 69 (50%) as compared with the controls 51 (36%) (p=0.005). Ten-year disease-free survival (DFS) remained significantly lower in the clodronate group (45% vs. 58%, p=0.01, respectively). This was especially seen in oestrogen receptor negative patients (25% vs. 58%, p=0.004, respectively). No significant overall survival difference was found between the groups. As previously reported 3-year adjuvant clodronate treatment did not prevent the development of bone metastases in node-positive breast cancer patients. A negative effect of clodronate on DFS by increasing the development of visceral metastases was still seen at 10 years, but this did not significantly compromise overall survival.Keywords
This publication has 19 references indexed in Scilit:
- Zoledronic acid reduces skeletal-related events in patients with osteolytic metastasesCancer, 2001
- Oral clodronate in breast cancer patients with bone metastases: a randomized studyJournal of Internal Medicine, 1999
- Pamidronate Reduces Skeletal Morbidity in Women With Advanced Breast Cancer and Lytic Bone Lesions: A Randomized, Placebo-Controlled TrialJournal of Clinical Oncology, 1999
- Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.Journal of Clinical Oncology, 1998
- Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.Journal of Clinical Oncology, 1996
- Bisphosphonates act on rat bone resorption through the mediation of osteoblasts.Journal of Clinical Investigation, 1993
- Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer.Journal of Clinical Oncology, 1993
- Controlled Clinical Study on the Use of Dichloromethylene Diphosphonate in Patients with Breast Carcinoma Metastasizing to the SkeletonOncology, 1991
- The clinical course of bone metastases from breast cancerBritish Journal of Cancer, 1987
- DIPHOSPHONATES FOR OSTEOLYTIC METASTASESThe Lancet, 1985